GTXi (GTXI) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
GTXi (GTXI)

An SI Board Since March 2005

Posts	SubjectMarks	Bans	Symbol
85	11	0	GTXI

Emcee: tuck	Type: Unmoderated

Introduction Market Data Compact

Recent IPO GTXI has seen steady insider buying of late, which is pretty unusual for this period of time. Starting this to see if anyone wants to explore why.

It's actually got a marketed product, Toremifene Citrate, which is currently approved for front line metastatic breast cancer. It's been on the market for years, and GTXI is not worth billions, so I gather it's no great shakes. The same molecule is being developed, perhaps in different formulations and dosages, for conditions related to prostate cancer. The rest of the pipe is early, two SARMS in PI, another molecule preclinical.

This is first pass stuff; I'll get up to speed, but I basically know nothing other than the above. All help appreciated.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
85	Recently upgraded value assigned at $19 by Citigroup , might want to add some re	2MAR$	-	2/5/2012
84	OT <nice to see you in the neighbourhood again..> Well I have been paroled	kenhott	-	12/15/2011
83	Ken, nice to see you in the neighbourhood again. Jason	tnsaf	-	10/24/2011
82	OTReply- No, sorry for running you in circles but you got me at 180. Thanks for	kenhott	-	10/24/2011
81	<reply> GTXI is not the same company from the High Pin days. They have g	kenhott	-	10/24/2011
80	>>GTx Announces Top Line Results of Phase III Clinical Trial Evaluating To	tuck	-	5/25/2010
79	Form 8-K for GTX INC /DE/ 26-Mar-2010 Entry into a Material Definitive Agreeme	tnsaf	-	3/27/2010
78	OT- One can never have too many tax deductions.	kenhott	-	3/4/2010
77	OT - That's very kind of you Ken, and there's no need really, I mean fol	idos	-	3/4/2010
76	OT-Your info made me money. Without your pointer, I would have done nothing. I	kenhott	-	3/4/2010
75	My guess is that GTXI is trying to salvage something here.	kenhott	-	3/3/2010
74	>What, you couldn't find anything interesting on page 228, tenth paragrap	idos	-	3/3/2010
73	<See page 128, 2nd paragraph> What, you couldn't find anything intere	kenhott	-	3/2/2010
72	MRK has discontinued internal development of MK-2866 (which is a SARM) under thi	idos	-	3/2/2010
71	What happened to GTXI should be a cautionary tale that parents use to tell their	kenhott	-	11/4/2009
70	<reply> I did get a chance to listen to the cc. The FDA basically threw	kenhott	-	11/2/2009
69	amgn and gtxi could cost share some consultants.	keokalani'nui	-	11/2/2009
68	GTx Receives Complete Response Letter from FDA for Toremifene 80 mg New Drug App	kenhott	-	11/2/2009
67	Looks like a complete response letter.	kenhott	-	11/2/2009
66	Change re: High grade PIN trial inside PR. GTx, Inc. Reports Second Quarter 200	kenhott	-	8/10/2009
65	Ostarine Offsets Cancer Cachexia in Phase II Trial Elsevier Global Medical News.	tnsaf	-	5/4/2009
64	GTx says FDA will rule on bone drug by Oct. 30 Thursday March 5, 10:12 am ET GTx	tnsaf	-	3/5/2009
63	>>Your goggle hit "Conclusions: These results indicate that toremifen	tuck	-	1/23/2009
62	Your goggle hit "Conclusions: These results indicate that toremifene is ...	kenhott	-	1/23/2009
61	>>In light of today's EMEA warning on toremifene, does anyone who foll	tuck	-	1/22/2009

Go to reply# or date (mm/dd/yy):